A double-blind, placebo-controlled, randomized clinical study of the effects of vardenafil on human nasal patency

American Journal of Rhinology

Volumn 22, Issue 3, 2008, Pages 276-279

  Aydin, Erdinc ^a,b   Hizal, Evren ^a   Onay, Ovsen ^a   Ozgen, Basak ^a   Turhan, Baris ^a   Zaimoglu, Murat ^a   Peskircioglu, Levent ^a   Budakoglu, Isil Irem ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Baskent Universitesi Ankara Hastanesi   (Turkey)

Author keywords

Acoustic rhinometry; Adverse effect; Double blind; Local decongestant; Nasal congestion; Nasal obstruction; Phosphodiesterase 5 inhibitors; Placebo controlled; Vardenafil; Visual analog scale

Indexed keywords

DECONGESTIVE AGENT; PLACEBO; VARDENAFIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; NOSE CAVITY; NOSE OBSTRUCTION; RANDOMIZED CONTROLLED TRIAL; RHINOMETRY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

ADULT; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NASAL CAVITY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROGNOSIS; PROSPECTIVE STUDIES; RHINOMETRY, ACOUSTIC; SULFONES; TRIAZINES; VASODILATOR AGENTS;

EID: 45349083079     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/ajr.2008.22.3169     Document Type: Article

References (18)

1. Weiss B, and Hait WN. Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Annu Rev Pharmacol Toxicol 17:441-477, 1977.
2. Francis SH, and Corbin JD. Phosphodiesterase-5 inhibition: The molecular biology of erectile function and dysfunction. Urol Clin North Am 32:419-429, 2005.
3. Lin CS, Lin G, and Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med 2:478-491, 2005.
4. Kiroglu AF, Bayrakli H, Yuca K, et al. Nasal obstruction as a common side-effect of sildenafil citrate. Tohoku J Exp Med 208:251-254, 2006.
5. Motamed M, Sandhu D, and Murty GE. Sildenafil and nasal obstruction. J Otolaryngol 32:259-261, 2003.
6. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270:83-90, 1993.
7. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 151:54-61, 1994.
8. Corbin JD, and Francis SH. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem 274:13729-13732, 1999.
9. Moreland RB, Hsieh G, Nakane M, et al. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther 296:225-234, 2001 Feb.
10. Seftel AD. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. Curr Pharm Des 11:4047-4058, 2005.
11. Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother 6:75-84, 2005.
12. Kim NN. Phosphodiesterase type 5 inhibitors: A biochemical and clinical correlation survey. Int J Impot Res 15(suppl 5):S13-S19, 2003.
13. Kim CM, Kim YS, Sunwoo S, et al, Korea Post-Marketing Surveillance Research Group. Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. Int J Impot Res 19:393-387, 2007.
14. Kamel A, Khaouli R, Sabha M, et al. The real-life safety and efficacy of vardenafil: An international post-marketing surveillance study of 2824 patients from the Middle East. Clin Drug Investig 27:339-346, 2007.
15. van Ahlen H, Zumbe J, Stauch K, et al. The real-life safety and efficacy of vardenafil: An international post-marketing surveillance study-Results from 29 358 German patients. J Int Med Res 33:337-348, 2005.
16. Cheng E. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 U.S. patients. J Sex Med 4:432-439, 2007.
17. Lam DJ, James KT, and Weaver EM. Comparison of anatomic, physiologic, and subjective measures of the nasal airway. Am J Rhinol 20:463-470, 2006.
18. Stewart MG, and Smith TL. Objective versus subjective outcomes assestment in rhinology. Am J Rhinol 19:529-535, 2005.